Clinical Trials · NCT01592279
GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients
- Phase
- Phase 4
- Recruitment status
- Unknown
- Sponsor
- Hadassah Medical Organization
- Enrollment
- 124
- Start date
- Jun 2012
- Locations
- See registry
- Primary endpoint
- The primary end point is the change in HbA1C relative to baseline after 3 months treatment with liraglutide in uncontrolled type 1 diabetic patients. The expected change is 1% reduction from baseline.